Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Drugs Offer Hope for Migraine Prevention

April 23, 2014 11:11 am | News | Comments

Two new studies may offer hope for people with migraine. Both studies involve drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started. Read more...         

TOPICS:

Sales of Controversial Hep C Drug Total $2.27B

April 23, 2014 11:08 am | News | Comments

Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi - launched in the United States during December and approved in Europe in January - totaled more than $2 billion in its first full quarter on the market, and it said quarterly net income tripled. Read more...

TOPICS:

Glioblastoma Vaccine Hits Primary Endpoints in Phase 1

April 23, 2014 11:03 am | News | Comments

Immatics Biotechnologies GmbH, Cancer Research UK and Cancer Research Technology announced that they have entered a license agreement to continue developing its cancer vaccine IMA950 for glioblastoma after positive results from a Phase 1 trial. Read more...

TOPICS:
Advertisement

Blood Pressure Drug Prevents Epilepsy After Brain Injury

April 23, 2014 10:52 am | News | Comments

Between 10 and 20% of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy. Read more...   

TOPICS:

Bayer Submits Riociguat for PAH in Japan

April 23, 2014 10:42 am | News | Comments

Bayer HealthCare has filed riociguat for the treatment of pulmonary arterial hypertension (PAH) for regulatory approval in Japan. Read more...                               

TOPICS:

FDA Fast Tracks OncoGenex Drug for Prostate Cancer

April 23, 2014 10:38 am | News | Comments

OncoGenex Pharmaceuticals Inc. announced that the FDA has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer. Read more...

TOPICS:

Alexion's Soliris Gets EC Orphan Status for New Treatment

April 23, 2014 10:30 am | News | Comments

Alexion Pharmaceuticals Inc. announced that the European Commission has granted an orphan drug designation to Soliris (eculizumab) for the prevention of graft rejection following solid organ transplantation. Read more...          

TOPICS:

Molecules Discovered for Neurodegenerative Diseases

April 22, 2014 1:02 pm | News | Comments

Researchers from NeuroPhage Pharmaceuticals Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. Read more...

TOPICS:
Advertisement

NIH, Broadview Ventures Fund Stroke Study

April 22, 2014 12:33 pm | News | Comments

ZZ Biotech announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial evaluating the safety, tolerability and activity of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke. Read more...

TOPICS:

Sentinel, Oncothyreon Collaborate on Cancer Drugs

April 22, 2014 12:13 pm | News | Comments

Sentinel Oncology Ltd., the small molecule drug discovery company, announced it has signed a collaboration agreement with Oncothyreon Inc. for development of Sentinel’s Checkpoint Kinase 1 (Chk1) program, under which Sentinel is eligible to receive milestone payments. Read more...

TOPICS:

AbbVie Submits NDA for Hep C Regimen

April 22, 2014 11:54 am | News | Comments

AbbVie submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. Read more...

TOPICS:

Pfizer Reports Positive Phase 3 Results for Psoriasis Drug

April 22, 2014 11:46 am | News | Comments

Pfizer announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program evaluating the efficacy and safety of tofacitinib, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. Read more...

TOPICS:

FDA Accepts Gilead NDAs for HIV Drugs

April 22, 2014 11:34 am | News | Comments

Gilead Sciences Inc. announced that the FDA has accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or “boosting” agent, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. Read more...

TOPICS:

On the Hunt for Safer Alternatives to NSAIDs

April 22, 2014 10:54 am | News | Comments

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure or sudden cardiac death. This has prompted a decade-plus search for safer, but still effective, alternatives to these drugs. Read more...

TOPICS:

Sanofi Selling Cell Therapy, Regenerative Medicine Businesses

April 22, 2014 10:43 am | News | Comments

Aastrom Biosciences Inc. announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million. Read more...            

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading